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Abstract
To study how virus evolution affects neutralization sensitivity and to determine changes that occur in and around epitopes,
we tested the ability of 13 anti-HIV-1 gp120 (anti-V2, anti-V3, anti-CD4bd and anti-carbohydrate) human monoclonal
antibodies (mAbs) to neutralize sequential viruses obtained from five HIV-1 chronically infected drug naı ¨ve individuals.
Overall, primary viruses collected from patients at first visit were resistant to neutralization by all anti-HIV-1 mAbs with the
exception of one virus sensitive to IgG1b12. Four of the five patients’ viruses evolved increased sensitivity to neutralization
by anti-V3 mAbs. Virus collected from a patient obtained 31 months later, evolved increased sensitivity to anti-V2, anti-V3,
and anti-CD4bd mAbs. Furthermore, the anti-V2 and anti-CD4bd mAbs also exhibited increased neutralization capacities
against virus collected from a patient 29 months later. Of the seven anti-V3 mAbs, five showed increased potency to
neutralize the evolved virus from a patient collected after 11 months, and three exhibited increased potency against viruses
from two patients collected 29 and 36 months later. Anti-V3 mAbs exhibited the most breadth and potency in neutralizing
the evolving viruses. Sequence analysis of the envelope regions revealed amino acid conservation within the V3 loop, while
most of the changes identified occurred outside the core epitopes and in particular within the C3 region; these may account
for increased neutralization sensitivity. These studies demonstrate that in vivo, HIV-1 can evolve increased neutralization
sensitivity to mAbs and that the spectrum of neutralization capacities by mAbs can be broader when studied in longitudinal
analysis.
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Introduction
To date, almost all studies that have examined the sensitivity of
human immunodeficiency virus type 1 (HIV-1) isolates to anti-
HIV-1 human monoclonal antibodies (mAbs) have been cross-
sectional and they show that only a few mAbs neutralize HIV-1
primary isolates. The lack of neutralization by most antibodies
has been attributed to a variety of reasons such as the occlusion of
the neutralization sensitive epitopes on primary HIV-1 isolates by
carbohydrate moieties, the absence of the specific epitope on the
intact HIV-1 virion and the differences in conformational
structures on the virions [1,2]. In addition to these factors that
contribute to neutralization resistance, HIV-1 primary isolates
can evolve over time to escape from autologous neutralization
through changes due to insertions and deletions, point mutations,
changes in glycan shielding and nonsynonymous changes
[3,4,5,6,7,8].
HIV-1 viral envelope regions, which have been identified to be
immunogenic and to which mAbs were developed include the
V1V2, V3, CD4-binding domain (CD4bd), CD4 induced antigen
(CD4i) and C5 regions of the gp120 [9]. The cluster I and II
regions of the gp41 have also been found to be immunogenic to
many mAbs [10,11,12]. Among the mAbs derived from the cells of
HIV-1 infected individuals and that neutralize a variety of primary
HIV-1 isolates in cross sectional studies, some are specific to
epitopes in the V3 loop (e.g. 447-52D), CD4bd (e.g. IgG1b12),
carbohydrate (e.g. 2G12), and others to epitopes in the MPER of
gp41 (e.g. 2F5 and 4E10) [13,14,15,16]. Antibodies directed at
epitopes in the V1 region are known to be type specific while
mAbs to V2 are cross-reactive but weakly neutralizing [17,18].
Although some lab strains (e.g. MN) or extensively in-vitro cultured
isolates (e.g SF162) are sensitive to neutralization by mAbs, many
of these antibodies do not neutralize HIV-1 primary isolates when
tested in cross sectional studies. However, several immunochem-
ical studies have revealed that many of these antibodies, especially
anti-V3 mAbs, bind to peptides, soluble proteins, recombinant
proteins and intact virions, suggesting that the epitopes are present
but in different forms [19].
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e17253Information is sparse on the evolution of sensitivity to
neutralization of HIV-1 primary isolates by antibodies that either
do or don’t neutralize viruses tested in cross sectional studies. It is
well known that viruses in infected individuals evolve to escape
from neutralization by autologous antibodies over time
[6,8,20,21,22]. No published study has demonstrated a scenario
whereby viruses in HIV-1 infected individuals evolve increase
sensitivity to their autologous antibodies. Instead, more virus
diversification and escape from neutralization is documented [8].
Casting this in the vaccine context raises the issue of the relevance
of virus neutralization sensitivity to heterologous antibodies and
virus evolution.
The current study examines the neutralization sensitivity to
anti-HIV-1 mAbs of viruses from 3 patients (ITM60, ITM27 and
ITM39) [23] as well as 2 other patients (NYU104 and 3506
[unpublished]), whose viruses were previously tested with plasma
to determine their neutralization sensitivity, and were shown to
exhibit increased neutralization sensitivity (ITM60, NYU104, and
3506 [unpublished]), no change in neutralization sensitivity
(ITM39), and decreased neutralization sensitivity (ITM27) [23].
Because the antibodies present in plasma are polyclonal, the use of
anti-HIV-1 mAbs directed at specific epitopes on HIV-1 virions
provides the opportunity to identify the specific epitopes that
exhibit the change in the neutralization patterns seen with the
polyclonal antibodies in plasma. Thus, in the present study, we
examined the neutralization sensitivity of the sequential HIV-1
primary isolates during their natural evolution in HIV-1 infected
drug naı ¨ve individuals to anti-HIV-1 mAbs directed at epitopes in
the V2, V3, CD4bd and carbohydrates of gp120.
Results
CD4 T cell profiles of study subjects
A portion of the sequential blood samples were collected from
the five HIV-1-infected subjects and used to determine the CD4
cell counts by FACScan. Their CD4 profiles are shown in figure 1
and reveal that all these subjects studied were asymptomatic
during the study period and were naive to antiretroviral drugs. At
the start of the study, the CD4 counts of three study subjects
(ITM27, ITM39, and NYU104) ranged between 411 and
437 cells/mm
3, while the CD4 counts of two study subjects
(ITM60 and 3506) was 1031 and 993 cells/mm
3. The CD4 counts
of ITM60 and NYU104 declined to 671 and 253 cells/mm3,
while the CD4 counts of two study subjects (ITM39 and 3506)
stayed relatively stable over time (499 and 750 cells/mm
3),
respectively. It was noted that the CD4 T cell count of subject
ITM27 increased from 415 to 767 cells/mm
3. Viruses isolated
from a portion of the blood sample that was used for CD4 count
determination were used for the neutralization studies described
below.
Neutralization by anti-V3 mAbs
Each of the seven anti-V3 mAbs, including 391/95-D, 447-
52D, 1006-15D, 2219, 694/98-D, 2442 and 2191, were serially
diluted at a range of 50-0.005 mg/ml and tested with the two
sequential viruses isolated at early and late time point from patient
ITM60, ITM27, ITM39 and 3506 infected with HIV-1 subtype B
strain as well as NYU104 infected with a CRF02_AG variant.
None of these mAbs neutralized the early virus from these patients
above 50% (Figures 2a, 2c, 2e, 2g and 2i). All seven mAbs
neutralized the later time point virus of ITM 60 (Figure 2b), with a
capacity as high as 88% (Figure 2b). The lowest concentration of
mAb needed for 50% neutralization (IC50) of the later time point
virus was 0.3 mg/ml, as shown by mAb 447-52D and 2191
(Table 1) and the highest IC50 was 2.1 mg/ml for mAb 694/98-D
(Table 1). Three mAbs (694/98-D, 391/95-D and 1006-15D)
exhibited .50% neutralization of the later time point virus of
NYU104. The specific IC50s required for 50% neutralization were,
5.9 mg/ml for mAb 391/95-D, 6.1 mg/ml for mAb 1006-15D, and
4.4 mg/ml for mAb 694/98-D (Table 1). This data suggests that
non-B subtype viruses can also evolve increased neutralization
sensitivity to clade B derived mAbs. Five mAbs exhibited $50%
neutralization at different concentrations against the virus taken 11
months later from patient 3506 (Figure 2f and Table 1). Of these
five mAbs, 2191 exhibited an IC50 of 1.5 mg/ml (Figure 2f and
Table 1) and an IC90 of 18.8 mg/ml (Figure 2f). Another mAb,
Figure 1. CD4 profile of HIV-1 infected study subjects. All the study subjects were asymptomatic. CD4 counts were determined by FACScan.
doi:10.1371/journal.pone.0017253.g001
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and an IC90 of 27.1 mg/ml (Figure 2f). While mAb 2219 exhibited
an IC50 of 20.5 mg/ml, the other two mAbs, 2442 and 694/98-D
exhibited an IC50 of 31.5 mg/ml and 35.1 mg/ml, respectively
(Table 1). Three of the seven anti-V3 mAbs neutralized (.50%)
virus isolated 36 months later from patient ITM27 (Figure 2h) but
none of the mAbs neutralized the late virus from patient ITM39
(Figure 2j). The most potent of the seven mAbs tested against the
late virus from patient ITM27 was mAb 2442 with an IC50 at
5.4 mg/ml and an IC90 of 47.5 mg/ml (Table 1). Furthermore,
IC50 was also achieved with mAb 2191 at a concentration of
5.5 mg/ml and mAb 447-52D at 30.6 mg/ml (Table 1).
Taken together, these data suggest that the viruses isolated at a
later time point from patients ITM60 showed increased neutral-
ization sensitivity to all the 7 anti-V3 mAbs tested, that from
NYU104, ITM27 and 3506 showed increased neutralization
sensitivity to 3–5 out of 7 anti-V3 mAbs, whereas the late time
point virus isolated from ITM39 was resistant to neutralization by
all the 7 anti-V3 mAbs as its early time point virus.
Neutralization by anti-V2, anti-CD4bd and anti-
carbohydrate mAbs
We examined the neutralization patterns of two anti-V2 mAbs
(697-D and 2158), three anti-CD4bd mAbs (559/64-D, 654-D and
IgG1b12) and one anti-carbohydrate mAb (2G12), with the
sequential viruses from all five patients; ITM60 (Figures 3a and
3b), NYU104 (Figures 3c and 3d), 3506 (Figures 3e and 3f),
ITM27 (Figures 3g and 3h) and ITM39 (Figures 3i and 3j). While
none of the mAbs neutralized the early viruses, with the exception
of IgG1b12 which neutralized virus from patient 3506, extensive
neutralization was achieved against the late time point viruses
from patients ITM60 and NYU104 (Figures 3b and 3d).
As shown in Figure 3b, the pattern of neutralization exhibited
by the three anti-CD4bd mAbs against the late virus from patient
ITM60 was similar when tested at concentrations ranging between
0.3–50 mg/ml. As noted for mAb IgG1b12, IC50 and IC90 were
achieved at concentrations of ,0.3 mg/ml and 41.7 mg/ml,
respectively. With mAb 654-D, an IC50 was also achieved at a
concentration of ,0.3 mg/ml (Table 1). For mAb 559/64-D, IC50
and IC90 were achieved at concentrations of 0.6 mg/ml and
45.8 mg/ml, respectively (Figure 3b and Table 1). For the two anti-
V2 mAbs tested, the IC50 for 2158 was 21.4 mg/ml and that for
697-D was 37.7 mg/ml (Figure 3b, Table 1). Thus, for all three
anti-CD4bd mAbs, IC50 was achieved at much lower concentra-
tions compared to the anti-V2 mAbs.
Of the three anti-CD4bd mAbs (559/64-D, 654-D and
IgG1b12) tested against the late virus from patient NYU104,
mAbs 559/64-D and IgG1b12 neutralized the virus with IC50 of
10.1 mg/ml and 10.5 mg/ml, respectively (Figure 3d, Table 1). For
the two anti-V2 mAbs tested, the IC50 for 2158 was 24.3 mg/ml
and that for 697-D was 50 mg/ml (Figure 3d, Table 1).
Interestingly, the late time point virus for NYU104 evolved
increased neutralization sensitivity to the anti-carbohydrate mAb,
2G12, with an IC50 of 3.7 mg/ml (Figure 3d, Table 1).
All the mAbs described above were also tested with the
sequential viruses from patient 3506. As shown in Figures 3e and
3f, IgG1b12 neutralized both early and late viruses from patient
3506, though exhibiting a higher neutralizing capacity against the
late virus. Specifically, the IC50 and IC90 titers for mAb IgG1b12
were achieved at 6.0 mg/ml and 24.9 mg/ml respectively for the
first time point virus (Figure 3e and Table 1), 0.4 mg/ml and
2.9 mg/ml respectively for the later time point virus, thus showing
a higher potency of neutralization of the later time point virus
(Figure 3f and Table 1).
Table 1. Anti-HIV-1 monoclonal antibody concentrations (mg/ml) required to yield 50% neutralization with the HIV-1 infected
patients’ sequential viruses.
Patient Virus
ITM60 NYU104 3506 ITM27 ITM39
Monoclonal Antibody Early Late Early Late Early Late Early Late Early Late
391/95-D .50 1.1 .50 5.9 .50 .50 .50 .50 .50 .50
447-52D .50 0.3 .50 .50 .50 .50 .50 30.6 .50 .50
1006-15D .50 0.4 .50 6.1 .50 5.5 .50 .50 .50 .50
Anti-V3 2219 .50 0.3 .50 .50 .50 20.5 .50 .50 .50 .50
694/98-D .50 2.0 .50 4.4 .50 35.1 .50 .50 .50 .50
2442 .50 0.5 .50 .50 .50 31.5 .50 5.4 .50 .50
2191 .50 0.3 .50 .50 .50 1.5 .50 5.5 .50 .50
697-D .50 37.7 .50 50 .50 .50 .50 .50 .50 .50
Anti-V2 2158 .50 21.4 .50 24.3 .50 .50 .50 .50 .50 .50
559/64-D .50 0.5 .50 10.1 .50 .50 .50 .50 .50 .50
Anti-CD4bd 654-D .50 ,0.3 .50 .50 .50 .50 .50 .50 .50 .50
IgG1b12 .50 ,0.3 .50 10.5 6.0 0.4 .50 .50 .50 .50
Anti-Carbohydrate 2G12 .50 .50 .50 3.7 .50 .50 .50 .50 .50 .50
doi:10.1371/journal.pone.0017253.t001
Figure 2. Neutralization curves of anti-V3 monoclonal antibodies against sequential viruses. Neutralization sensitivity of HIV-1 subtype B
and CRF02_AG viruses obtained sequentially from patient ITM60 (a and b), NYU104 (c and d), 3506 (e and f), ITM27 (g and h), and ITM39 (i and j) with
anti-V3 monoclonal antibodies. The dash horizontal line represents 50% neutralization.
doi:10.1371/journal.pone.0017253.g002
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sequential viruses from patient ITM27 and ITM39. None of the
mAb neutralized the early and late viruses from patient ITM27
(Figures 3g and 3h) and ITM39 (Figures 3i and 3j).
Examination of the presence of core epitopes on the
sequential viruses targeted by the mAbs
We examined the gp120 sequences to determine if changes
occurred within or outside defined core epitopes on the viral
envelopes for those viruses that exhibit changes in neutralization
sensitivity. Using the aliquots of the virus that were tested in the
neutralization studies, we sequenced the viral envelope regions and
analyzed the mutational changes by comparing the sequences
from the initial viral isolates with those from the later time points.
V3 epitopes
As shown in Figure 4, the V3 sequences of the sequential viruses
from patients ITM60, NYU104, 3506 and ITM27, which evolved
to become sensitive to anti-V3 mAbs, were examined. The lengths
of the V3 loops of the sequential viruses from all four patients were
the same (35 amino acids). Overall, the V3 sequences were fairly
constant over time, with only a few mutations noted in the later
time point virus compared with the virus from the first visit
(Figure 4).
The V3 sequence used to define the mAb core epitope was
derived from HIV-1 MN strain (www.hiv.lanl.gov) and the
epitopes targeted by each mAb are shown in Figure 4. We
compared the sequence of the HIV-1 MN-defined core epitope to
the sequence of the epitopes on the sequential viruses studied, and
correlated any differences in the sequence with neutralization
sensitivity to the corresponding mAb. The most significant changes
in the virus neutralization sensitivity to anti-V3 mAbs were noted
with the sequential viruses from patients ITM60 and 3506
(Figures 2b and 2f). With the exception of one patient (ITM27),
the core V3 sequence of the late time point viruses from all other
patients was similar to that of the first time point virus (Figure 4,
boxed). We then examined the sequences flanking the V3 loop,
including the C2 and C3 regions, and found that mutations had
occurred in these regions (data not shown and Figure 5a). The C3
region of the later time point virus from patient NYU104 that
exhibited an increase in sensitivity to three of the seven anti-V3
mAbs as well showed several amino acid changes (Figure 5b).
These results suggest that changes outside the V3 loop might also
have contributed to the increase in neutralization sensitivity to
anti-V3 mAbs.
The sequential viruses from patient 3506 exhibited an increase
in sensitivity to five of the seven anti-V3 mAbs (Figure 2f). While
the core epitope was similar to that of the initial virus, two changes
had occurred outside the core V3 epitope in the virus obtained 11
months later. The two mutations included a change from
threonine (T) to isoleucine (I) at position 2, and a change from
alanine (A) to threonine (T) at position 22 (Figure 4). The change
from hydrophilic threonine (T) to hydrobhobic isoleucine (I) at the
base of the V3 loop might change the orientation of this loop,
thereby better exposing the epitopes to anti-V3 antibodies
(Figure 4). Examination of the sequences in the C3 region also
revealed several changes (Figure 5c).
Of the four patients (ITM60, NYU104, 3506 and ITM27)
whose sequential viruses exhibited increased sensitivity to
neutralization by anti-V3 mAbs, those from patient ITM27
exhibited the weakest increase in neutralization sensitivity
(Figure 2h). The sequence of the core epitope from patient
ITM27’s last visit was different from that of the virus obtained
from the patient’s first visit (Figure 4). Furthermore, the virus
collected at the last time point visit from ITM27 exhibited the
greatest sequence change (n=3) in the V3 loop when compared to
the virus from the first visit. These changes occurred either within
the region of the core epitope (Figure 4a) or both within and near
the epitope (Figure 4b-e). The three changes occurred mainly
around the crown of the V3 loop and included a change from
histidine (H) to proline (P) at position 13, a change from alanine
(A) to glycine (G) at position 15, and a change from glycine (G) to
arginine (R) at position 17. Thus, the APGS motif at the tip of the
V3 loop was changed to a GPRS motif. This could be the reason
why ITM27 late virus became sensitive to anti-V3 mAbs. Outside
the region of the core epitope, the V3 loop sequences of the viruses
from the first and last visits were identical. Of note is that in the V3
loops of the sequential viruses, even when the core epitope was
present in the late time point virus, other mutations had occurred
outside this core epitope (Figure 4b). The mutations in the C2 and
C3 regions (data not shown and Figure 5d), might have helped in
unfolding and exposing the epitopes in the V3 region which these
antibodies target.
V2 epitopes
The V2 sequences of the sequential viruses from patient
ITM60 and NYU104 that evolved increase sensitivity to anti-V2
mAbs were aligned and changes in the entire V2 loop sequence
were examined. Several changes in the V2 sequence from the late
time point virus as compared to early time point virus were
identified. Unlike the constant nature of the V3 loop sequences
described above, more changes were found to occur in the V2
region for the late time point virus (Figure 6). These changes in
the sequence of the late time point viruses from patient ITM60
and NYU104 may well expose the epitope of anti-V2 mAbs and
increase neutralization.
CD4bd epitope (targeted by mAb IgG1b12)
We examined the changes in the amino acid sequence critical
for IgG1b12 binding in sequential viruses obtained from patients
ITM60, NYU104 and 3506. We found that although there were
changes in the in the C3 region sequence, the amino acids critical
for IgG1b12 binding had only one change for the late time point
virus from patient 3506 that included a change from threonine (T)
to alanine (A) at position 44 (Figure 5). No changes in amino acids
critical for these anti-CD4bd mAbs were observed in both time
point viruses from patient ITM60 and NYU104.
Discussion
Our present study demonstrates that both subtype B and
CRF02_AG viruses in some HIV-1 chronically-infected individ-
uals evolve to become more sensitive to neutralization by
antibodies directed at epitopes in the V2, V3 and CD4bd
(Figures 2 and 3). These data provide a clear indication that
Figure 3. Neutralization curves of anti-V2, anti-CD4bd, and anti-carbohydrate monoclonal antibodies against sequential viruses.
Neutralization sensitivity of HIV-1 subtype B and CRF02_AG viruses obtained from patient ITM60 (a and b), NYU104 (c and d), 3506 (e and f), ITM27 (g
and h), and ITM39 (i and j) with anti-V2, anti-CD4bd, and anti-carbohydrate monoclonal antibodies. The dash horizontal line represents 50%
neutralization.
doi:10.1371/journal.pone.0017253.g003
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studies are inadequate to define the neutralization spectrum of
mAb neutralization with primary HIV-1 isolates. Therefore,
longitudinal studies of neutralization capacities are needed to
determine important neutralization-sensitive epitopes and to better
identify immunogenic regions that will be suitable for a vaccine
that prevents infection by all HIV-1 strains.
Studies that have examined virus evolution and autologous
neutralization in HIV-1 infected patients during acute and chronic
infection have demonstrated that over time, viruses in these
individuals undergo diversification and escape from neutralization
[6,8]. A potent vaccine should, by definition, induce ‘‘heterologous
neutralizing’’ antibodies, as the infecting HIV-1 virion will differ
from the vaccine strain. In recent studies, we examined the
neutralization sensitivities of sequential HIV-1 subtype B strains in
chronically infected patients to heterologous HIV-1 plasma
samples [23]. The studies clearly demonstrated that while
sequential HIV-1 viruses from some patients maintain their
neutralization sensitivity to antibodies in heterologous HIV-1
plasma, as was the case for patient ITM39, other patients’ viruses
evolve to escape neutralization, as was the case for ITM27 [23].
While these studies with heterologous HIV-1 plasma revealed for
the first time that viruses can evolve to become more sensitive to
neutralization, it remained unclear which antibodies were
specifically responsible for these phenomenon, due to the
polyclonal nature of antibodies in plasma. Our present study
demonstrates that indeed, viruses in some HIV-1 chronically
infected individuals evolve increased neutralization sensitivity to
antibodies directed at well defined viral epitopes. In particular,
anti-V3, anti-V2, and anti-CD4bd mAbs exhibited increased
neutralization capacity to viruses collected from two patients,
ITM60 and NYU104, collected 31 and 29 months, respectively
after initial virus that was resistant to neutralization by these same
antibodies. This is the first report clearly demonstrating that as
viruses evolve in their hosts, mutations occur that render them
more susceptible to neutralization by specific mAbs. The
possibility therefore exists that the antibodies in heterologous
HIV-1 plasma samples that exhibited increased neutralization
capacity to the sequential virus from this patient could in part be
attributed to anti-V2, anti-V3 and anti-CD4bd antibodies.
However, the pattern of neutralization sensitivity for ITM27 with
the heterologous plasma and the anti-V3 mAbs may be attributed
to the lack of such antibodies in the plasma.
In general, HIV-1 primary isolates are often resistant to
neutralization by plasma from HIV-1 infected patients and by
many anti-HIV-1 mAbs. Of the mAbs tested in this study, the anti-
V3 and anti-CD4bd mAbs have been documented in other studies
to neutralize primary isolates at concentrations similar to those
seen in our study with the later time point viruses from the patients
[24,25]. As shown in Table 1, the IC50 concentrations needed to
yield 50% neutralization were low (0.3–2 mg/ml), in particular, for
the anti-V3 mAbs for the late time point virus from patient
ITM60, while higher concentrations of the same mAbs were
needed to neutralize the later time point viruses from patient
NYU104 (4.4–6.1 mg/ml) and 3506 (1.5–35.5 mg/ml). Such
Figure 4. V3 loop sequences of the sequential viruses. The
sequences shown represent the consensus sequence from 3-11 clones.
The sequences were derived from the same aliquot of virus culture
supernatant that was used in the neutralization assay. The core epitope
to which the anti-HIV-1 monoclonal antibodies were directed is boxed.
The epitope specificity of the monoclonal antibodies (mAb) was
mapped using HIV-1 MN V3 peptides and the core epitope sequences
of the MN peptide are shown along with the monoclonal antibody.
doi:10.1371/journal.pone.0017253.g004
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neutralization for different viruses have also been reported for
these and other mAbs in other studies [24,25]. These differences
could be due to differences in the level of exposure of mAb
epitopes on different viruses. For example, the V3 loop is better
exposed on virus SF162 and this virus is much more sensitive to
anti-V3 antibodies than other viruses whose V3 loops are less well
exposed [26]. As such viruses with a better exposed epitope will
possibly need a lower antibody concentration to achieve 50%
neutralization than viruses whose V3 loops are less well exposed.
In addition, several other factors such as specific mutations within
and outside the epitope as well as folding and glycosylation
patterns can contribute to differences in neutralization sensitivities
requiring different mAb concentraions to achieve 50% neutrali-
zation [4,5,27]. These factors are discussed below with respect to
the various mAbs used in this study and the mutational patterns
observed based on sequence information.
The V3 loop sequences as well as the amino acids critical for
mAb IgG1b12 binding remained relatively constant for the
sequential viruses; yet, the viruses became more sensitive to
neutralization. This suggests that changes outside the core epitope
contribute to increased neutralization sensitivity. Because several
changes were identified outside the core epitopes, especially in C3
region, the possibility exists that these mutations may have caused
changes in the structural conformation exposing the V3 loop and
increasing its accessibility to the antibodies. In addition to changes
that occurred outside the core epitope, which might have resulted
in better exposure and increased neutralization sensitivity, point
mutations (Figure 4) might have also contributed to increased
neutralization sensitivity. For example, in the case of patient
ITM27, the early time point virus lacked G (glycine) at position 15
and R (arginine) at position 17, which are critical for the V3 loop
b-turn. The R (arginine) at position 18 for mAbs 391/95-D, 447-
52D and 694/98-D, and the G (glycine) at position 15 for mAbs
1006-15D, 2219, 2442 and 2191, are very critical for binding
[2,14,28,29]. The late virus for patient ITM27 has a G (glycine) at
position 15 and an R (arginine) at position 18. This may have
contributed in part to the increased neutralization sensitivity seen
with the late time point virus from patient ITM27. However, as
this virus was resistant to polyclonal antibodies in plasma, it is
possible that Abs that neutralize the virus were absent in the
plasma samples examined in our previous studies [23]. The V2
and V3 regions interact with each other and form a complex
epitope [30,31]. Several changes were identified in the V2 region.
There is a possibility that mutations in V2 region may affect the
exposure of V3 epitope and that might have contributed to
increased neutralization sensitivity.
The late time point virus of NYU104 evolved increased
neutralization sensitivity to the anti-carbohydrate mAb, 2G12.
The 2G12 epitope is centered on the high-mannose and/or hybrid
glycans of asparagines residues 295, 332, and 392, with peripheral
glycans from 386 and 448 on either flank [32]. These residues are
present on C2, C3, C4 and V4 region. Examination of these
residues found all five N-linked glycosylation sites in both the early
and late time point virus (data not shown). However, several other
changes were identified in C2, C3, C4, and V4 regions from the
early to the late time point virus isolate. Therefore, though the
epitope required for 2G12 binding was present in the initial virus,
its resistance to neutralization could be due to masking of the
epitope through certain amino acid changes that probably caused
folding patterns. However, we can only hypothesize that the
changes in the sequences we observed around the vicinity of the
epitope probably caused an increased accessibility to the antibody
through better exposure resulting in increased neutralization. The
data presented on the mutational patterns in figures 4, 5, 6 now
provides the opportunity for studies that would identify and
distinguish mutations that contribute to increased neutralization
sensitivity or escape.
Viral evolution toward or away from neutralization sensitivity is
likely to be an ongoing process. It now remains to be seen whether
these viruses that evolve increase neutralization sensitivity will
continue to be sensitive or will become resistant over time. This
Figure 5. C3 region sequences of the sequential viruses. The sequences shown represent the consensus sequence from 3–11 clones. The
sequences were derived from the same aliquot of virus culture supernatant that was used in the neutralization assay.
doi:10.1371/journal.pone.0017253.g005
Figure 6. V2 region sequences of the sequential viruses. The
sequences shown represent the consensus sequence from 3–11 clones.
The sequences were derived from the same aliquot of virus culture
supernatant that was used in the neutralization assay.
doi:10.1371/journal.pone.0017253.g006
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points from such individuals. Furthermore, our studies have
examined viruses isolated from patient PBMC which might not
represent the whole viral quasispecies present in the patients.
However, to avoid the possibility that the neutralization sensitive
viruses detected in the later time point from patients was not due
to a preferential selection, adaptation and possibly infectivity
differences by such variants that may be present even in the early
time point, if different donor PBMCs were used for virus isolation
and amplification in different donor PBMCs, the same PBMC
donor pool were used in all virus isolation and amplification.
Because different variants within a quasispecies can exhibit
different neutralization patterns, thus, the often lack of 100%
neutralization sensitivity; different variants within the patients will
also need to be examined for their neutralization sensitivity over
time and the proportion of variants that are susceptible to
neutralization be determined.
It is important to begin to understand whether viruses that
evolve increased neutralization sensitivity to heterologous anti-
bodies also induce neutralizing antibodies in their hosts that would
neutralize their autologous or other heterologous viruses. In initial
experiments in which we tested the sequential plasma with their
contemporaneous viruses (early and late) from patient NYU104
and ITM60 whose viruses evolved increased neutralization
sensitivity we observed that these viruses were resistant to
neutralization by their autologous and contemporaneous plasma
samples (data not show). The results of our studies therefore reveal
that while viruses mutate to escape neutralization by autologous
antibodies [6,7], some do evolve increased neutralization sensitiv-
ity to heterologous antibodies as demonstrated in our previous
studies with heterologous plasma [23] and in the present study
with mAbs. These results therefore, suggest that mutations that
occur and lead to escape from neutralization by autologous
antibodies may be different from those that lead to increased
neutralization sensitivity by heterologous antibodies. Though the
number of subjects studied, five, may be small, the findings are
important for vaccine design and raise the need for more extended
studies.
In conclusion, the results of this study are counter intuitive
revealing that viruses in patients can evolve increase neutralization
sensitivity. However, the antibodies tested are heterologous to the
viruses, which should be the basis for a protective vaccine because
the infecting virus will almost always be heterologous to the
antibodies induced by the vaccine strain. Understanding how
viruses evolve and how their evolution affects their sensitivity to
different antibodies should improve our knowledge of the
relationship between genetic evolution, immunity, and vaccine
design.
Materials and Methods
HIV-1 infected patients and sequential virus isolation
The sequential viruses tested were isolated from the PBMCs of
four HIV-1 subtype B and one CRF02_AG chronically infected
drug naı ¨ve patients. Three of the four HIV-1 subtype B infected
patients (ITM60, ITM27 and ITM39) from whom sequential
viruses were obtained have been described in our previous studies
[23]. Briefly, these patients were followed at the Institute of
Tropical Medicine (ITM) in Antwerp; they were drug naı ¨ve and
remained asymptomatic during a three-year study period. PBMCs
from these patients were obtained by Ficol-Hypaque density
gradient centrifugation; they were kept in liquid nitrogen in
Antwerp and shipped in dry ice to our lab in New York for the
studies described here. PBMCs from the two other subjects, 3506
(subtype B) and NYU104 were similarly obtained by Ficol-
Hypaque as was for the three subtype B infected subjects from
Antwerp described above. The two sequential viruses from
patients ITM60, ITM27 and ITM39 were isolated at 31, 36 and
26 months intervals, respectively. The fourth HIV-1 subtype
infected patient (3506) from whom two sequential viruses were
obtained, was also chronically infected, drug naı ¨ve, remained
asymptomatic and regularly consulted at the Veterans Affairs
Medical Center, New York, New York. The two sequential viruses
from patient 3506 were obtained at an 11 month interval. The
fifth patient (NYU104), who was chronically infected with a
CRF02_AG variant in Africa, was asymptomatic and drug naı ¨ve,
and the two sequential viruses studied were obtained 29 months
apart. Ethical clearances have been approved from IRB of
Institute of Tropical Medicine, Antwerp, Belgium; National
Ethical Committee of Cameroon and New York University
Medical center.
Virus isolation and virus stock preparation from all the five
patients studied were performed using two donor’s PBMCs that
were pooled. This approach using the same donor PBMCs was to
avoid differences that may exist in virus selection, adaptation, and
infectivity when using different donor PBMCs ([33,34]). First, we
isolated virus from patient by co-culturing each of 5610
6 patient
PBMCs with of 5610
6 of the pooled HIV negative donor PBMCs.
To prepare stocks of these viruses for the neutralization studies,
1 ml aliquot of culture supernatant containing the virus isolated
from patients’ PBMCs was used to infect the PBMCs of 3-day
phytohemaglutinin-stimulated HIV-negative pooled donors
[19,35]. After 2–3 weeks of culture in IL-2 supplemented media,
the culture supernatant from infected PBMCs was aliquoted
(1 ml/tube) and stored at 280uC until use. Virus stock was titrated
in TZM-bl cells as previously described, [36] and tested in
neutralization assays, as described below.
Anti-HIV-1 human mAbs
Thirteen mAbs were used to test the neutralization sensitivity of
sequential viruses from the HIV-1 infected individuals. The mAbs
were directed at epitopes in the V3 (391/95-D, 447-52D, 1006-
15D, 2219, 694/98-D, 2442 and 2191) [2,14,28,29], V2 (697-D
and 2158) [17,37], CD4bd (559/64-D, 654-D and IgG1b12)
[38,39,40]}, and anti-carbohydrate (2G12) regions [16] of gp120.
Human mAb 860-55D to parvovirus B19 [41] was used as a
negative control.
Neutralization assay
TZM-bl cell lines carrying CD4 and both CCR5 and CXCR4
were used in the neutralization assays as previously described [36].
Two fold serial dilutions of the mAbs were used starting at a
concentration of 50 mg/ml up to 0.005 mg/ml and tested with
100TCID50 of the virus in the TZM-bl neutralization assay. Thus,
culture supernatant containing PBMC derived viruses was pre-
incubated with mAb for 1 hour at 37uC and added to TZM-bl
cells (10,000 cells in 100 ml of growth medium containing 25 mg/
ml DEAE dextran and 1 mM indinavir) in a 96-well plate. The
plates were incubated for 2 days after which 150 ml of supernatant
was removed and 50 ml of Bright Glo (Bright-Glo luciferase Assay
system, Promega, Madison, Wisconsin) was added and incubated
for 2 min at room temperature. Following this incubation period,
80 ml of the mixture was transferred to a 96 well black plate and
luminescence was measured using a Lumimark Plus System
microplate reader (Bio-Rad Laboratories, Hercules, CA). Reduc-
tion of infectivity was determined by comparing the relative
luminescence units (RLU) in the presence of anti-HIV-1 mAbs
and negative control wells in which the viruses were mixed with
HIV Evolution and Neutralization Sensitivity
PLoS ONE | www.plosone.org 9 February 2011 | Volume 6 | Issue 2 | e17253the human mAb 860-55D to parvovirus B19. All experiments were
performed in triplicate wells. The average of the neutralization
results from the triplicate wells for each virus/mAb test
combination was expressed as percent neutralization. All the
neutralization assays were repeated two-three times and the
average of the independent neutralization assays was taken to
determine the neutralization sensitivities of the various tested
mAbs.
RNA extraction and RT-PCR
Viral RNA was extracted from virus culture supernatant (the
same aliquot used for neutralization) as described by Boom et al,
[42] followed by reverse transcription using Oligo dT primer
(Promega Corporation, Madison, WI) and AMV reverse tran-
scriptase (Access RT-PCR system; Promega Corporation, Madi-
son, WI). Viral RNA was heated at 70uC for 10 minutes with the
Oligo dT primer and immediately chilled on ice prior to the
addition of the enzyme mixture, followed by one cycle of 48uC for
1 hour. The Expand Long Template PCR System (Roche,
Mannheim, Germany) was used for the first-round and second-
round PCR amplification of the envelope gp160 gene according to
the instructions given by the manufacturer. Amplification was
performed with outer primers R8005B (forward) 59 GCC-
CTGGAAGCATCCAGGAAGTCAGCCT 39 (HXB2 location
5857–5884) and ENV N (reverse) 59 CTGCCAATCAGGGAAG-
TAGCCTTGTGT 39 (HXB2 location 9171–9145), and with
inner primers R8003B (forward) 59 AAAAGGCTTAGGCAT-
CTCTATGGCAGGAAGAAGCG 39 (HXB2 location 5950–
5985) and R8004B (reverse) 59 ATATGTCGACCTCGAGA-
TACTGCTCCCACCCCTTCTGCTACTG 39 (HXB2 location
8912–8870). The amplification protocol for the first- round PCR
was one cycle at 94uC for 2 minutes, followed by 30 cycles at 94uC
for 10 seconds, 55uC for 30 seconds and 68uC for 8 minutes,
ending with a single extension cycle at 68uC for 10 minutes. For
the second-round PCR, the protocol started with one cycle at
94uC for 2 minutes, followed by 10 cycles at 94uC for 10 seconds,
60uC for 30 seconds and 68uC for 8 minutes; it continued with an
additional 20 cycles at 94uC for 15 seconds, 62uC for 35 seconds
and 68uC for 8 minutes, ending with a single extension cycle at
68uC for 10 minutes.
Cloning and Sequencing
PCR products were cloned into the Topo TA cloning vector
and plasmids were transformed into chemically competent E. coli
cells according to manufacturer’s recommendations (Invitrogen,
Carlsbad, CA). Between 3 and 10 colonies selected by Kanamycin
(Kan) resistance and blue-white screening were grown in 3 ml of
LB+Kan broth overnight. Plasmids were purified using the
QIAprep Spin Miniprep kit (Qiagen Inc, Valencia, CA), and
analyzed by PCR to determine insert size. Positive clones were
sequenced at the 59 and 39 ends with the universal T3 and T7
primers. Primer walking was performed to obtain the full
sequence. Sequences were assembled using the Pregap and Gap
programs from the Staden software package [43]. Sequences were
assessed for nonsense mutations using the Gene Cutter program
from the Los Alamos HIV Sequence database website (http://
hiv-web.lanl.gov/content/sequence/gene-cutter/cutter.html).
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